A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A monoclonal gammopathy of undetermined significance (MGUS) occurs in up to 2 percent of persons 50 years of age or older. Reliable predictors of progression have not been identified, and information on prognosis is limited. METHODS: We identified 1384 patients residing in southeastern Minnesota in whom MGUS was diagnosed at the Mayo Clinic from 1960 through 1994. The primary end point was progression to multiple myeloma or another plasma-cell cancer. RESULTS: During 11,009 person-years of follow-up, MGUS progressed in 115 of the 1384 patients to multiple myeloma, IgM lymphoma, primary amyloidosis, macroglobulinemia, chronic lymphocytic leukemia, or plasmacytoma (relative risk of progression, 25.0, 2.4, 8.4, 46.0, 0.9, and 8.5, respectively). The overall relative risk of progression was 7.3 in these patients as compared with the white population of the Iowa Surveillance, Epidemiology, and End Results program. In 32 additional patients, the monoclonal protein concentration increased to more than 3 g per deciliter or the percentage of plasma cells in the bone marrow increased to more than 10 percent (smoldering multiple myeloma) but without progression to overt myeloma or related disorders. The cumulative probability of progression was 12 percent at 10 years, 25 percent at 20 years, and 30 percent at 25 years. The initial concentration of serum monoclonal protein was a significant predictor of progression at 20 years. CONCLUSIONS: The risk of progression of MGUS to multiple myeloma or related disorders is about 1 percent per year.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MGUS progresses to multiple myeloma or related malignancy a rate of 1% per year.16,17”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [16]
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Asymptotically Efficient Rank Invariant Test Procedures
Peto, R., & Peto, J. (1972) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344317 · Cited by 3,393
Gooley, T. A., Leisenring, W., Crowley, J., & Storer, B. E. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19990330)18:6<695::aid-sim60>3.0.co;2-o · Cited by 2,688
History of the Rochester Epidemiology Project
Melton, L. J. (1996) · Mayo Clinic Proceedings · doi:10.4065/71.3.266 · Cited by 1,443
Self-citationKyle, R., Linos, A., Beard, C., Linke, R., Gertz, M., O'Fallon, W., & Kurland, L. (1992) · Blood · doi:10.1182/blood.v79.7.1817.1817 · Cited by 657
Self-citationMonoclonal gammopathy of undetermined significance
Kyle, R. A. (1978) · The American Journal of Medicine · doi:10.1016/0002-9343(78)90522-3 · Cited by 607
Self-citationFrequency of Pathological Proteins (M‐components) in 6,995 Sera from an Adult Population
AXELSSON, U., BACHMANN, R., & HÄLLÉN, J. (1966) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1966.tb05453.x · Cited by 436
“Benign” Monoclonal Gammopathy—After 20 to 35 Years of Follow-Up
KYLE, R. A. (1993) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)60015-9 · Cited by 338
Self-citationThe Analysis of Mortality by the Subject-Years Method
Berry, G. (1983) · Biometrics · doi:10.2307/2530817 · Cited by 278
Research works printed but not linked: 4
- Hallen J, 1966, Acta Med Scand Suppl, 462, 1
- Kyle RA, Katzmann JA. Immunochemical characterization of immunoglobulins. In: Rose NR, Conway de Macario E, Folds JD, Lane HC, Nakamura RM, eds. Manual of clinical laboratory immunology. 5th ed. Washington, D.C.: ASM Press, 1997:156-76.
- Kyle RA, 1999, Blood, 94, 537a
- Fonseca R, 1999, Blood, 94, 663a
Cited by
Items 401–500 of 1,000
New horizons in our understanding of precursor multiple myeloma and early interception
dos Santos, D. M. C., Toenges, R., Bertamini, L., Alberge, J.-B., & Ghobrial, I. M. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00755-x · Cited by 36
“SMM is a clinical entity that identifies patients with a consequential burden of disease (10–60% clonal plasma cells in the bone marrow, an M-spike concentration of ≥3 g dl −1 or ≥500 mg of protein in the urine in 24 h) who lack end organ damage 6–10 .”
MicroRNAs in multiple myeloma and related bone disease.
Rossi, M., Tagliaferri, P., & Tassone, P. (2015) · PubMed · doi:10.3978/j.issn.2305-5839.2015.12.13 · Cited by 38
What is the significance of monoclonal gammopathy of undetermined significance?
Atkin, C., Richter, A. G., & Sapey, E. (2018) · Clinical Medicine · doi:10.7861/clinmedicine.18-5-391 · Cited by 41
Inomata, T., Tahara, N., Nakamura, K., Endo, J., Ueda, M., Ishii, T., Kitano, Y., & Koyama, J. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13473 · Cited by 26
Hardy, N. M., Grady, C., Pentz, R. D., Stetler‐Stevenson, M., Raffeld, M. A., Fontaine, L. S., Babb, R. R., Bishop, M., Caporaso, N. E., & Marti, G. E. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06862.x · Cited by 35
“…decades of follow-up in large populations has established the rate of progression to myeloma with some precision (i.e. approximately 1% per year) (Kyle et al, 2002), for MBL all that is known is that at least a portion of those with clones will progress to clinical CLL/small lymphocytic lymphoma…”
BackgroundInfluentialImpact of metformin on the progression of MGUS to multiple myeloma
Boursi, B., Mamtani, R., Yang, Y., & Weiss, B. M. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1236375 · Cited by 35
“[4] The average risk of progression from MGUS to MM is about 1% per year.[5] Given the low risk of progression and the lack of available agents with acceptable efficacy to toxicity ratios, chemoprevention interventions to reduce the development of MM in MGUS have not been studied.”
BackgroundA General Machine Learning Framework for Survival Analysis
Bender, A., Rügamer, D., Scheipl, F., & Bischl, B. (2021) · Lecture notes in computer science · doi:10.1007/978-3-030-67664-3_10 · Cited by 50
Martín, P., Santón, A., & Bellas, C. (2004) · Histopathology · doi:10.1111/j.1365-2559.2004.01834.x · Cited by 35
“The risk that MGUS may evolve to a malignant state (MM, lymphoma IgM serum monoclonal protein, primary amyloidosis, macroglobulinaemia, chronic lymphocytic leukaemia or plasmacytoma) is about 1– 2% of cases per year, and patients are at risk of progression even after 25 years or more of stable MGUS.(2) The differences…”
BackgroundInfluentialCurrent Therapeutic Strategy for Multiple Myeloma
Suzuki, K. (2013) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hys215 · Cited by 37
Naina, H. V. K., Harris, S., Dispenzieri, A. A., Cosio, F. G., Habermann, T. M., Stegall, M. D., Dean, P. G., Prieto, M., Kyle, R. A., Rajkumar, S. V., et al. (2012) · American Journal of Nephrology · doi:10.1159/000337482 · Cited by 35
Self-citationMultiparametric flow cytometry profiling of neoplastic plasma cells in multiple myeloma
Johnsen, H. E., Bøgsted, M., Klausen, T. W., Gimsing, P., Schmitz, A., Kjærsgaard, E., Damgaard, T., Voss, P., Knudsen, L. M., Mylin, A. K., et al. (2010) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.20523 · Cited by 37
Telomere shortening in patients with plasma cell disorders
Cottliar, A., Pedrazzini, E., Corrado, C., Engelberger, M. I., Narbaitz, M., & Slavutsky, I. R. (2003) · European Journal Of Haematology · doi:10.1034/j.1600-0609.2003.00157.x · Cited by 34
Multiple Myeloma: How Far Have We Come?
Anderson, K. C. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.1.15 · Cited by 35
Sperry, B. W., Saeed, I. M., Raza, S., Kennedy, K. F., Hanna, M. A., & Spertus, J. A. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.08.045 · Cited by 33
Martinot, M., Oswald, L., Parisi, E., Etienne, É., Argy, N., Grawey, I., Briel, D. D., Zadeh, M. M., Fédérici, L., Blaison, G., et al. (2013) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2013.10.020 · Cited by 33
Protein Electrophoresis and Immunoglobulin Analysis in HIV-Infected Patients
Konstantinopoulos, P. A., Dezube, B. J., Pantanowitz, L., Horowitz, G. L., & Beckwith, B. A. (2007) · American Journal of Clinical Pathology · doi:10.1309/qwtqfga9fxn02yme · Cited by 33
Neurologic aspects of plasma cell disorders
Sobol, U., & Stiff, P. J. (2013) · Handbook of clinical neurology · doi:10.1016/b978-0-7020-4087-0.00073-5 · Cited by 37
Lindqvist, E. K., Landgren, O., Lund, S. H., Turesson, I., Hultcrantz, M. L., Goldin, L. R., Björkholm, M., & Kristinsson, S. Y. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2859-8 · Cited by 33
“Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic, pre-malignant condition with an average risk of progression to MM or other lymphoproliferative disorders of 1 % per year [3].”
BackgroundNeurologic Complications of Lymphoma, Leukemia, and Paraproteinemias
Mauermann, M. L. (2017) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000468 · Cited by 33
“MGUS carries a risk of progression to a hematologic malignancy of 1% per year.(39) Peripheral neuropathy.”
BackgroundThe normal counterpart to the chronic lymphocytic leukemia B cell
Caligaris‐Cappio, F., & Ghia, P. (2007) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2007.02.005 · Cited by 38
Dubot, P., Astudillo, L. M., Therville, N., Sabourdy, F., Stirnemann, J., Levade, T., & Andrieu‐Abadie, N. (2020) · Cancers · doi:10.3390/cancers12020475 · Cited by 33
“MGUS is a pre-malignant condition that predisposes to MM with a 1% risk of transformation per year in the general population [32].”
BackgroundRecommendations for Management of Secondary Antibody Deficiency in Multiple Myeloma
Giralt, S., Jolles, S. R. A., Kerre, T. C. C., Lazarus, H. M., Mustafa, S. S., Papanicolaou, G. A., Ria, R., Vinh, D. C., & Wingard, J. R. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.05.008 · Cited by 36
Monoclonal gammopathy of undetermined significance: a new proposal of workup
Mangiacavalli, S., Cocito, F., Pochintesta, L., Pascutto, C., Ferretti, V. V., Varettoni, M., Zappasodi, P., Pompa, A., Landini, B., Cazzola, M., et al. (2013) · European Journal Of Haematology · doi:10.1111/ejh.12172 · Cited by 33
Genomewide profiling of copy‐number alteration in monoclonal gammopathy of undetermined significance
Mikulášová, A., Smetana, J., Wayhelová, M., Janyšková, H., Sandecká, V., Chyra, Z., Almáši, M., Jarkovský, J., Gregora, E., Kessler, P., et al. (2016) · European Journal Of Haematology · doi:10.1111/ejh.12774 · Cited by 34
Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma
Kyle, R. A., & Rajkumar, S. V. (2007) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2007.08.005 · Cited by 38
Self-citationMonoclonal gammopathy of undetermined significance
Rajkumar, S. V., & Kumar, S. (2025) · New England Journal of Medicine · doi:10.1056/nejmra2412716 · Cited by 31
Self-citationLandgren, O. (2010) · Hematology · doi:10.1182/asheducation-2010.1.295 · Cited by 40
Long non-coding RNAs in B-cell malignancies: a comprehensive overview
Nobili, L., Ronchetti, D., Taìana, E., & Neri, A. (2017) · Oncotarget · doi:10.18632/oncotarget.17303 · Cited by 32
Autoimmunity, Infections, and the Risk of Monoclonal Gammopathy of Undetermined Significance
Sigurbergsdóttir, A. Ý., Löve, Þ. J., & Kristinsson, S. Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.876271 · Cited by 34
“Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic, premalignant plasma cell disorder, preceding multiple myeloma (MM) and related disorders, including Waldenström’s macroglobulinemia and amyloid light-chain (AL) amyloidosis (1, 2).”
BackgroundPrevalence of monoclonal gammopathy of undetermined significance in Thailand
Watanaboonyongcharoen, P., Nakorn, T. N., Rojnuckarin, P., Lawasut, P., & Intragumtornchai, T. (2012) · International Journal of Hematology · doi:10.1007/s12185-011-0995-4 · Cited by 34
“7% at 10 years [7], were also lower than that of the US report [3].”
BackgroundMailankody, S., Mena, E., Yuan, C. M., Balakumaran, A., Kuehl, W. M., & Landgren, O. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2010.525725 · Cited by 34
“Although it has been known for some time now that patients with MGUS have an increased risk of progression to MM and other related malignancies [6,7], it is only recently that two independent studies have provided convincing evidence to show that virtually all cases of MM are preceded by premalignant MGUS [13,14].”
Dietary intake is associated with risk of multiple myeloma and its precursor disease
Þórðardóttir, M., Lindqvist, E. K., Lund, S. H., Costello, R., Burton, D., Steingrímsdóttir, L., Korde, N., Mailankody, S., Eiríksdóttir, G., Launer, L. J., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0206047 · Cited by 33
Șengül, Ș., Li, M., & Batuman, V. (2009) · Journal of Nephrology · doi:10.1093/joneph/22.1.17 · Cited by 31
Systemic Capillary Leak Syndrome Associated with Compartment Syndrome and Rhabdomyolysis
Sanghavi, R., Åneman, A., Parr, M. J., Dunlop, L. C., & Champion, D. (2006) · Anaesthesia and Intensive Care · doi:10.1177/0310057x0603400308 · Cited by 31
2025 Inborn errors of immunity practice parameter
Orange, J. S., Chinen, J., Horner, C. C., Kobrynski, L. J., Ballow, M. C., Butte, M. J., Chandrakasan, S., Chinn, I. K., Satter, L. F., Freeman, A. F., et al. (2026) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2025.10.026 · Cited by 35
McMaster, M. L., & Caporaso, N. E. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06845.x · Cited by 32
“…by three concurrent criteria: (1) presence of a serum monoclonal IgM protein concentration of <30 g/l; (2) absence of morphological evidence of bone marrow infiltration by lymphoma or plasma cells (i.e., <10% involvement); and (3) absence of signs or symptoms attributable to WM (Kyle et al, 2002).”
BackgroundPiot, J. M., Royer, M., Schmidt, A., Hoppé, E., Gardembas, M., Bourrée, T., Hunault, M., François, S., Boyer, F., Ifrah, N., et al. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.71 · Cited by 30
Bringing mass spectrometry into the care of patients with multiple myeloma
Murray, D. L. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03364-2 · Cited by 32
“M-proteins are a relatively common laboratory finding occurring in approximately 3% of adults over the age of 50 [1].”
BackgroundMonoclonal Gammopathy of Undetermined Significance: A Comprehensive Review
Kaur, J., Valisekka, S. S., Hameed, M., Bandi, P. S., Varma, S., Onwughalu, C. J., Ibrahim, H., & Mongia, H. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.02.004 · Cited by 36
The Current Status and Future of Multiple Myeloma in the Clinic
Jagannath, S., Kyle, R. A., Palumbo, A. P., Siegel, D. S. D., Cunningham, S. A., & Berenson, J. R. (2010) · Clinical Lymphoma Myeloma & Leukemia · doi:10.3816/clml.2010.n.003 · Cited by 33
Self-citationSpira, D., Weisel, K. C., Brodoefel, H., Schulze, M., Kaufmann, S., & Horger, M. (2011) · Academic Radiology · doi:10.1016/j.acra.2011.09.016 · Cited by 30
Suzuki, K. (2012) · Clinical and Experimental Nephrology · doi:10.1007/s10157-012-0684-5 · Cited by 38
“1) [5].”
Abdominal adipose tissue in MGUS and multiple myeloma
Veld, J. V., O’Donnell, E., Reagan, M. R., Yee, A. J., Torriani, M., Rosen, C. J., & Bredella, M. A. (2016) · Skeletal Radiology · doi:10.1007/s00256-016-2425-4 · Cited by 30
“with a life-long risk of progression to MM, which is about 1 % per year [5].”
BackgroundInfluentialCastillo, J. J., & Gertz, M. A. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1217527 · Cited by 30
“5% per year.[35,36] The evidence supporting an increased risk of other secondary malignancies in patients with MGUS is scarce.”
BackgroundCurrent and future imaging modalities for multiple myeloma and its precursor states
Tan, E., Weiss, B. M., Mena, E., Korde, N., Choyke, P. L., & Landgren, O. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.573036 · Cited by 30
“The average risk of progression to multiple myeloma is approximately 1% per year for patients with MGUS and 10% per year for patients with SMM [46,47].”
BackgroundThe spectrum of pulmonary amyloidosis
Riehani, A., & Soubani, A. O. (2023) · Respiratory Medicine · doi:10.1016/j.rmed.2023.107407 · Cited by 29
Global hypomethylation in myeloma is associated with poor prognosis
Sive, J. I., Feber, A., Smith, D., Quinn, J., Beck, S., & Yong, K. (2015) · British Journal of Haematology · doi:10.1111/bjh.13506 · Cited by 29
Monoclonal gammopathy and neuropathy
Lozeron, P., & Adams, D. (2007) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3282ef79e3 · Cited by 30
Long‐term follow‐up of a population based cohort with monoclonal proteinaemia
Schaar, C. G., le Cessie, S., Snijder, S., Franck, P., Wijermans, P., Ong, C., & Kluin‐Nelemans, H. C. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07423.x · Cited by 30
“…or lymphoplasmacytic lymphoma (Giraldo et al, 1991; Blade et al, 1992; van de Poel et al, 1995; Baldini et al, 1996; Pasqualetti et al, 1997; Vuckovic et al, 1997; Colls, 1999; van de Donk et al, 2001; Gregersen et al, 2001a; Anagnostopoulos et al, 2002; Cesana et al, 2002; Kyle et al, 2002).”
BackgroundInfluentialVanderWall, K., Daniels‐Wells, T. R., Penichet, M. L., & Lichtenstein, A. K. (2013) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2013007934 · Cited by 34
Sattianayagam, P. T., Hawkins, P. N., & Gillmore, J. D. (2009) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.09.59 · Cited by 37
Recent advances in multiple myeloma: a Korean perspective
Hong, J., & Lee, J. H. (2016) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2015.408 · Cited by 31
“MM is almost always preceded by MGUS, an asymptomatic pre-malignant stage with a low burden of serum M-protein and plasma cells in the bone marrow [5].”
BackgroundRajkumar, S. V., Bergsagel, P. L., & Kumar, S. K. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.12.001 · Cited by 30
Self-citationM ONOCLONAL G AMMOPATHIES OF U NDETERMINED S IGNIFICANCE
Kyle, R. A., & Rajkumar, S. V. (2002) · Reviews in Clinical and Experimental Hematology · doi:10.1046/j.1468-0734.2002.00076.x · Cited by 29
Self-citationAdvancements in Nanomedicine for Multiple Myeloma
Detappe, A., Bustoros, M. W., Mouhieddine, T. H., & Ghoroghchian, P. P. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.04.005 · Cited by 29
Oncolytic Viruses for Multiple Myeloma Therapy
Calton, C. M., Kelly, K. R., Anwer, F., Carew, J. S., & Nawrocki, S. T. (2018) · Cancers · doi:10.3390/cancers10060198 · Cited by 28
Gavriatopoulou, M., Βoultadaki, A., Koutoulidis, V., Ntanasis‐Stathopoulos, I., Bourgioti, C. I., Malandrakis, P., Fotiou, D., Migkou, M., Kanellias, N., Eleutherakis‐Papaiakovou, E., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00360-9 · Cited by 28
Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader
Yu, X., Wang, J., Gong, W., Ma, A., Shen, Y., Zhang, C., Liu, X., Cai, L., Liu, J., Wang, G. G., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02618-5 · Cited by 30
Lee, D. J., El‐Khoury, H., Tramontano, A. C., Alberge, J.-B., Perry, J. F., Davis, M. I., Horowitz, E. M., Redd, R. A., Sakrikar, D. S., Barnidge, D. R., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2023010843 · Cited by 32
The Challenge of Systemic Immunoglobulin Light-Chain Amyloidosis (AL)
Palladini, G. O., & Comenzo, R. L. (2012) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-007-5416-4_22 · Cited by 30
Morris, K. L., Tate, J. R., Gill, D. S., Kennedy, G., Wellwood, J., Marlton, P. V., Bird, R. J., Mills, A. K., & Mollee, P. N. (2007) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2007.01368.x · Cited by 28
Keratopathy of Multiple Myeloma Masquerading as Corneal Crystals of Ocular Cystinosis
Kleta, R., Blair, S. C., Bernardini, I. M., Kaiser‐Kupfer, M. I., & Gahl, W. A. (2004) · Mayo Clinic Proceedings · doi:10.4065/79.3.410 · Cited by 28
Bortezomib as a Treatment Option in Patients With Waldenström Macroglobulinemia
Dimopoulos, M. A., Chen, C. I., Kastritis, E., Gavriatopoulou, M., & Treon, S. P. (2010) · Clinical Lymphoma Myeloma & Leukemia · doi:10.3816/clml.2010.n.015 · Cited by 28
Disorders of Peripheral Nerves
Katirji, B., & Koontz, D. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0434-1.00101-8 · Cited by 28
Dispenzieri, A. A., Lacy, M. Q., & Greipp, P. R. (2004) · Springer eBooks · doi:10.1007/978-3-662-08885-2_3 · Cited by 28
Živković, S., Lacomis, D., & Lentzsch, S. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190903111922 · Cited by 28
“Patients with IgM or IgA gammopathies are also at higher risk of conversion to malignancy than patients with IgG monoclonal protein [54].”
BackgroundMultistep Tumorigenesis of Multiple Myeloma: Its Molecular Delineation
Iida, S., & Ueda, R. (2003) · International Journal of Hematology · doi:10.1007/bf02983776 · Cited by 30
“significance (MGUS) or smoldering myeloma (SMM) [2].”
BackgroundRasmussen, T., Theilgaard‐Mönch, K., Hudlebusch, H. R., Lodahl, M., Johnsen, H. E., & Dahl, I. M. S. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04577.x · Cited by 31
“Patients diagnosed with MGUS represent a heterogeneous group and, of those who will progress, only two out of three will develop MM (Kyle et al, 2002), suggesting that the genetic basis for one out of three of MGUS patients has no relationship to MM.”
BackgroundA 55-year-old man with hypogammaglobulinemia, lymphopenia, and unrelenting cutaneous warts
Lynn, J., Knight, A. K., Kamoun, M., & Levinson, A. I. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.02.033 · Cited by 28
Gene expression profiling and multiple myeloma
Shaughnessy, J. D., Zhan, F., Barlogie, B., & Stewart, A. K. (2005) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2005.02.003 · Cited by 30
Advanced Imaging of Multiple Myeloma Bone Disease
Hansford, B. G., & Silbermann, R. W. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00436 · Cited by 31
“Patients with MGUS and SMM have an overall risk of progression to MM of 1 and 10% per year, respectively (9), however individuals within each group have variable risks of disease progression.”
BackgroundRole of Specific B-Cell Receptor Antigens in Lymphomagenesis
Thurner, L., Hartmann, S., Neumann, F., Hoth, M., Stilgenbauer, S., Küppers, R., Preuss, K., & Bewarder, M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.604685 · Cited by 29
Biological aspects of angiogenesis in multiple myeloma
Otjacques, E., Binsfeld, M., Noël, A., Beguin, Y. P., Cataldo, D. D., & Caers, J. (2011) · International Journal of Hematology · doi:10.1007/s12185-011-0963-z · Cited by 30
“Gene expression studies in MGUS and MM plasma cells show that malignant plasma cell differ from normal plasma cells, but there is no significant difference between plasma cells of MGUS and MM patients [4, 5].”
BackgroundMussap, M., Pietrogrande, F., Ponchia, S., Stefani, P. M., Sartori, R., & Plebani, M. (2006) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2006.112 · Cited by 27
“In patients with MGUS, the rate of increase in M-protein is the most important predictor of progression to a plasma-cell disorder (3).”
BackgroundTargeting EZH2 in Multiple Myeloma—Multifaceted Anti-Tumor Activity
Alzrigat, M., Jernberg‐Wiklund, H., & Licht, J. D. (2018) · Epigenomes · doi:10.3390/epigenomes2030016 · Cited by 28
Epidemiology of Multiple Myeloma
Baris, D., Brown, L. M., Andreotti, G., & Devesa, S. S. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3764-2_28 · Cited by 29
Granulocyte transfusion therapy: randomization after all?
Drewniak, A., & Kuijpers, T. W. (2009) · Haematologica · doi:10.3324/haematol.2009.013680 · Cited by 29
Immunophenotypic studies of monoclonal gammopathy of undetermined significance
Olteanu, H., Wang, H., Chen, W., McKenna, R. W., & Karandikar, N. J. (2008) · BMC Clinical Pathology · doi:10.1186/1472-6890-8-13 · Cited by 33
Low CD27 Expression in Plasma Cell Dyscrasias Correlates With High-Risk Disease
Morgan, T. K., Zhao, S., Chang, K. L., Haddix, T. L., Domanay, E., Cornbleet, P. J., Arber, D. A., & Natkunam, Y. (2006) · American Journal of Clinical Pathology · doi:10.1309/elgmgx81c2utp55r · Cited by 27
“Plasmacytoma (n = 17) 99 (1) 50 (10)† 23 (5) 61(9) 8 (2) 1 (1) 3 (3) PCL (n = 15) 97 (2) 14 (6)‡ 37 (3) 31 (6)§ 20 (4)§ 4 (1) 10 (3) Myeloma (n = 160) 64 (2) 47 (3) 77 (6)‡ 73 (6) 34 (4)‡ 9 (1) 10 (1) MGUS (n = 8) 15 (3) 90 (14)‡ 99 (19)‡ 99 (28)§ 31 (5)§ 9 (1) 9 (1)”
Mauermann, M. L. (2014) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000455879.99050.26 · Cited by 36
“MGUS is a generally benign condition; however, it carries a transformation rate to symptomatic plasma cell disorders of approximately 1% annually.(1) High-risk factors for transformation include M protein of 15 g/L or greater, elevated free light-chain ratio (ratio of kappa to lambda free light chains), and non-IgG pr…”
BackgroundLozano, E., Díaz, T., Mena, M.-P., Suñé, G., Calvo, X., Calderón, M., Pérez-Amill, L., Rodríguez, V., Perez-Galan, P., Roué, G., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701622 · Cited by 26
“However, the annual rate of malignant transformation from MGUS to MM is 1% (6), indicating that mechanisms of control may prevent proliferation of aberrant PCs.”
BackgroundPrognosis of young patients with monoclonal gammopathy of undetermined significance (MGUS)
Li, P., Rajkumar, S. V., Kapoor, P., Buadi, F. K., Dispenzieri, A. A., Gertz, M. A., Lacy, M. Q., Kyle, R. A., & Kumar, S. K. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00406-6 · Cited by 26
Self-citationDai, X.-P., Li, M., & Geng, F. (2017) · Biochemistry (Moscow) · doi:10.1134/s0006297917070082 · Cited by 26
Monoclonal gammopathy of “ocular” significance
Karakus, S., Gottsch, J. D., Caturegli, P., & Eghrari, A. O. (2019) · American Journal of Ophthalmology Case Reports · doi:10.1016/j.ajoc.2019.100471 · Cited by 26
Multiple Myeloma and Immunosecretory Disorders
Shaheen, S. P., Talwalkar, S. S., & Medeiros, L. J. (2008) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e31817cfcd6 · Cited by 26
Multiple myeloma, chronic lymphocytic leukaemia and associated precursor diseases
Landgren, O., & Kyle, R. A. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06866.x · Cited by 30
“For this subset, risk of progression is likely substantially lower than the reported average 1% risk per year for unselected MGUS patients (Kyle et al, 2002; Landgren et al, 2006a).”
BackgroundSelf-citationGaucher disease and monoclonal gammopathy: A report of 17 cases and impact of therapy
Grosbois, B., Rosé, C., Noël, E., Serratrice, J., Dobbelaere, D., Gressin, V., Cherin, P., Hartmann, A., Javier, R., Clerson, P., et al. (2009) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2009.04.002 · Cited by 26
Kyle, R. A., Rajkumar, S. V., Therneau, T. M., Larson, D. R., Plevak, M. F., & Melton, L. J. (2005) · Clinical Lymphoma · doi:10.3816/clm.2005.n.011 · Cited by 26
Self-citationA Recursive General Regression Neural Network (R-GRNN) Oracle for classification problems
Bani-Hani, D., & Khasawneh, M. T. (2019) · Expert Systems with Applications · doi:10.1016/j.eswa.2019.06.018 · Cited by 27
Role of microRNAs in Diagnosis, Prognosis and Management of Multiple Myeloma
Soliman, A. M., Teoh, S. L., Mahakkanukrauh, P., & Das, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207539 · Cited by 26
Multiple Myeloma: 18F-FDG-PET/CT and Diagnostic Imaging
Mihailovic, J. M., & Goldsmith, S. J. (2014) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2014.08.002 · Cited by 26
“MGUS may also evolve into MM or Waldenstrom macroglobulinemia and rarely into lymphoma, primary amyloidosis, or chronic lymphocytic leukemia.(8) Staging of MM”
BackgroundWaxman, A. J., Kuehl, M. W., Balakumaran, A., Weiss, B. M., & Landgren, O. (2010) · Clinical Lymphoma Myeloma & Leukemia · doi:10.3816/clml.2010.n.053 · Cited by 26
“25 Rather, the diagnosis of SMM includes patients who fit at least 3 distinct clinical pictures: (1) abnormally active but stable MGUS; (2) slowly increasing M-protein or percent marrow plasma cells without detectable endorgan damage; and (3) highly progressive disease with end-organ damage that is not yet detectable…”
BackgroundBhutani, M., Türkbey, B., Tan, E., Korde, N., Kwok, M., Manasanch, E. E., Tageja, N., Mailankody, S., Roschewski, M. J., Mulquin, M., et al. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1090572 · Cited by 26
Reappraisal of risk factors for monoclonal gammopathy of undetermined significance
Boursi, B., Weiss, B. M., Haynes, K., Mamtani, R., & Yang, Y. (2016) · American Journal of Hematology · doi:10.1002/ajh.24355 · Cited by 27
“loidosis among patients with MGUS is about 1% per year [11].”
BackgroundMultiple myeloma: Experience of an institute in limited resource setting
Jacob, L. A., Babu, M., Lakshmaiah, K. C., Babu, K. G., Lokanatha, D., Rajeev, L. K., Lokesh, K. N., Rudresha, A. H., Agarwal, A., & Garg, S. (2017) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_87_17 · Cited by 25
Monoclonal gammopathy of undetermined significance, multiple myeloma, and osteoporosis
Bouvard, B., Royer, M., Chappard, D., Audran, M., Hoppé, E., & Legrand, É. (2010) · Joint Bone Spine · doi:10.1016/j.jbspin.2009.12.002 · Cited by 26
The significance of monoclonal gammopathy of undetermined significance
Kyle, R. A., & Kumar, S. K. (2009) · Haematologica · doi:10.3324/haematol.2009.013961 · Cited by 29
“In order to confirm the findings of the 241 Mayo Clinic patients from the USA and other countries which may be subject to referral bias, we conducted a study of 1,384 patients with MGUS from the 11 counties of Southeastern Minnesota evaluated at the Mayo Clinic from 1960 to 1994.(12) The median age at diagnosis was 72…”
MethodSelf-citationRichardson, P. G. G., Laubach, J. P., Mitsiades, C. S., Schlossman, R. L., Hideshima, T., Redman, K., Chauhan, D., Ghobrial, I. M., Munshi, N. C., & Anderson, K. C. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08791.x · Cited by 29
“Other features include hyperviscosity, amyloidosis and recurrent infections (Kyle et al, 2002).”
BackgroundUpdates and Ongoing Challenges in Imaging of Multiple Myeloma: AJR Expert Panel Narrative Review
Wu, F., Bernard, S., Fayad, L. M., Ilaslan, H., Messiou, C., Moulopoulos, L. A., & Mulligan, M. E. (2021) · American Journal of Roentgenology · doi:10.2214/ajr.21.25878 · Cited by 25
Eyþórsson, E. S., Rögnvaldsson, S., Þorsteinsdóttir, S., Long, T. E., Reed, E. R., Sigurðardóttir, G. Á., Viðarsson, B., Onundarson, P. T., Agnarsson, B. A., Sigurðardóttir, M. S., et al. (2024) · Annals of Internal Medicine · doi:10.7326/m23-2540 · Cited by 25
Metadata
- Authors
- Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Offord, J. R., Larson, D. R., Plevak, M. F., & Melton, L. J.
- Affiliations
- Mayo Clinic (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-02-21
- Volume
- 346
- Issue
- 8
- Pages
- 564-569
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2000655497
- Cited by
- 1,475
- References
- 17
- Citations by year
- 2026: 32 · 2025: 51 · 2024: 66 · 2023: 48 · 2022: 62 · 2021: 65 · 2020: 66 · 2019: 56 · 2018: 67 · 2017: 62 · 2016: 59 · 2015: 63 · 2014: 74 · 2013: 87 · 2012: 63
- FWCI
- 23.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA6 2242, P01CA062242)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Keywords
- monoclonal gammopathy of undetermined significance, progression to multiple myeloma, prognosis, plasma cell neoplasms, AL amyloidosis, macroglobulinemia, chronic lymphocytic leukemia, plasmacytoma, smoldering multiple myeloma, bone marrow plasma cells, risk prediction
- MeSH terms
- Adult, Aged, Amyloidosis, Follow-Up Studies, Humans, Leukemia, Lymphoid, Lymphoma, Waldenstrom Macroglobulinemia, Middle Aged, Multiple Myeloma, Paraproteinemias, Probability, Prognosis, Risk Factors, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.